Abstract 13P
Background
The phase II ALTER1202 trial demonstrated that patients who received anlotinib after failing at least two systemic chemotherapy regimens exhibited improved progression-free survival (PFS) and overall survival (OS) compared to the placebo group. In an effort to further enhance outcomes for small-cell lung cancer patients who have exhausted first-line platinum-based chemotherapy options, researchers are investigating the combination of anlotinib and penpulimab, a novel PD-1 inhibitor.
Methods
This open-label, single-arm, multi-center, phase II exploratory study enrolled patients with small-cell lung cancer who had previously undergone platinum-based chemotherapy. Patients received a combination therapy consisting of penpulimab (200mg every three weeks) and anlotinib (10mg daily), following a 2-week on and 1-week off schedule, until disease progression, unacceptable toxicity, or study discontinuation. The primary objective was to assess antitumor activity using the RECIST v1.1 criteria, focusing on the objective response rate (ORR). Secondary objectives included evaluating antitumor activity through the disease control rate (DCR), duration of response (DOR), PFS, OS, and assessing the safety and tolerability of this combination therapy.
Results
As of September 17, 2023, 38 patients were enrolled in the study and had received treatment. Of these 38 patients, 38 were evaluable using RECIST criteria, revealing an ORR of 26.30% (10 out of 38) and a DCR of 68.42% (26 out of 38). The median PFS was 4.36 months, with 6-month and 12-month PFS rates of 21.05% and 10.53%, respectively. The median DOR was 8.03 months, and the median OS was 15.71 months. Among the patients, 26 out of 38 (68.42%) experienced treatment-related adverse events, with 10 patients (26.32%) reporting grade 3 or higher adverse events. The most common adverse events related to anlotinib were hepatic injury, hematoxicity, and hypertension.
Conclusions
The combination of penpulimab and anlotinib showed promising clinical benefits and a favorable safety profile in small-cell lung cancer patients after platinum-based chemotherapy.
Clinical trial identification
NCT05001971.
Legal entity responsible for the study
Hunan Provincial Cancer Hospital.
Funding
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
47TiP - A real-world study of multiparametric prediction of the efficacy of immune checkpoint inhibitors in combination with chemotherapy for advanced non-small cell lung cancer
Presenter: Zihan Zhou
Session: Poster Display
51P - Phase 1B (Ph1b), MESOVAX clinical trial of pembrolizumab (P) and dendritic cell vaccine (DCvax) in advanced pleural and peritoneal mesothelioma (M): preliminary results
Presenter: Laura Ridolfi
Session: Poster Display
52P - The dependence of TKI-resistant lung cancer cells on EGFR increases sensitivity to EGFR-CAR NK.
Presenter: Sumei Chen
Session: Poster Display
53P - Integrin-_v_6 targeted CAR T-cells in an immunocompetent orthotopic model of pancreatic cancer
Presenter: Nicholas Brown
Session: Poster Display
55P - DPP9 promotes renal cancer PD-L1 expression through SHMT2-BRISC complex
Presenter: wei zhang
Session: Poster Display
56P - FOXM1D in T cells promotes the transcription of PD-1 by interacting with HCFC1 and regulating the killing of renal cancer cells
Presenter: yue wang
Session: Poster Display
57P - Anatomical location of metastasis and composition of the final infusion product in metastatic melanoma (MM) patients treated with tumor-infiltrating lymphocytes (TIL)
Presenter: Joachim Stoltenborg Granhøj
Session: Poster Display
58P - Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers
Presenter: Liangping Li
Session: Poster Display
59P - Revolutionizing cell therapy testing by co-culturing 3D patient derived cancer models and circulating immune cells on Organ-on-chip platform
Presenter: silvia Scaglione
Session: Poster Display
60P - Adaptive NK cells as a therapeutic option for childhood leukaemia
Presenter: Zoya Eskandarian
Session: Poster Display